Close Menu

Back to Basics?

Analyst Tim Anderson says that Pfizer could cut back to become strictly a drug discovery firm. To do so, the company would have to strip itself of "divisions accounting for $32 billion of its $67 billion in sales," adds Matthew Herper at Forbes. Anderson says these "extremely bold" moves would be greeted warmly by investors, though Pfizer has not made any commitments one way or the other.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.